
Vaccine Up-Date 51st Annual Course in Drug Therapy – May 6, 2021



Brian J Ward McGill Division of Infectious Diseases Research Institute – MUHC

LEARNING OBJECTIVES


After this presentation, participants will be better able to:


- 1) Manage resistance to vaccination
- 2) Give appropriate vaccine advice to protect against pneumonia & herpes zoster
- 3) Decide which vaccines need boosters


	Conflict of Interest Statement (Last 5 Years)				
	Position in Pharma	Medical Officer for Medicago Inc. (Oct 2011 - present)			
	Consulting	Pfizer, Merck, Novartis, GSK, Sanofi Pasteur MSSS, US Dept of Justice (Vaccine Compensation Programs)			
	Contracts	Vaccine trials for virtually many companies			
	Shared Awards	Shared CIHR Team grant (Laval U, GSK) CIHR-Industry grant (Medicago) Shared CQDM grant (Medicago, Laval U, SNC Lavalin)			
	Occasional Speakers Honoraria	Pfizer, Sanofi Pasteur,Novartis			
	Investments	None			















Some Big Names have Hit Roadblocks Others are Wobbling

	Pre-Clinical	Phase 1	Phase 2	Phase 3
BNT/Pfizer				>
Oxford/AstraZeneca				>
Queesland			- 🎎	
Johnson & Johnson				>
Moderna Sanofi		14 A		\longrightarrow
Inovio		*		
Novavax				>
SinoPharm				>
SinoVac				>
Medicago		× ×		>
Merck		- X		<u>,</u>
CureVac Gamaleya				>
Bharat Biotech				>
CanSino				\rightarrow

Some Big Names have Hit Roadblocks Others are Wobbling

	Pre-Clinical	Phase 1	Phase 2	Phase 3
BNT/Pfizer Oxford/AstraZeneca Queesland Johnson & Johnson Moderna Sanofi Inovio Novavax SinoPharm SinoVac Medicago Merck CureVac	Pre-Clinical	Phase 1	Phase 2	Phase 3
Gamaleya Bharat Biotech				
CanSino	https://www.psychologytoday	.com/ca/blog/joyful-par	enting/201903/10-oct	u-ways-neip-anxious-child-calm-down



Impact of SARS-COV-2 on Other Vaccines **Increases in other Vaccine-Preventable Diseases**

2021, VOL. 17, NO. 2, 400-407 https://doi.org/10.1080/21645515.2020.1804776

Taylor & Francis Taylor & Francis Group


Vaccines and routine immunization strategies during the COVID-19 pandemic

Ener Cagri Dinleyici 💿 , Ray Borrow , Marco Aurélio Palazzi Safadi 💿 , Pierre van Damme , and Flor M. Munoz

Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey Vaccine Evaluation Unit, Public Health England, Manchester, UK Department of Pediatrics, Santa Casa De São Paulo, School of Pediatrics, São Paulo, Brazil: Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerg, Antwerg, Belgium Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA

ABSTRACT

ABSTRACT Severe acute respiratory syndrome coronavirus 2 related disease (COVID-19) is now responsible for one of the most challenging and concerning pandemics. By August 2020, there were almost 20 million confirmed cases worldwide and well over hall-million deaths. Since there is still no effective treatment or vaccine, non-pharmaceutical interventions have been implemented in an attempt to contain the spread of the virus. During times of quarantine, immunization practices in all age groups, especially routine childhood vaccines, have also been interupted, delayed, re-organized, or completely suspended. Numerous high-income as well as low- and middle-income countries are now experiencing a rapid decline in childhood immunization coverage rates. We will, inevitably, see serious consequences related to suboptimal control of vaccine-preventable diseases (VPDs) in children concurrent with or tolowing the pandemic. Routine pediatric immunizations of individual children at clinics, mass vaccination campaigns, and surveillance for VPDs must continue as much as possible during pandemic.











Episodes of Illness	715,073
Medical Visits	400,441
Hospitalizations	65,007
Deaths	6,796







Pneumococcal Conjugate Vaccines


Wyeth	Pfizer	GSK	P	PV
(Licensed)	(13-Valent)	(10-Valent)	(23 V	alent)
4	1	1	1	17f
6b	3	4	2	18c
9v	4	5	3	19a
14	5	6b	4	19f
19f	6a	7f	5	20
18 c	6b	9v	6b	22f
23f	7f	14	7f	23f
	9v	19f	8	33f
	14	18c	9n	
	19a	23f	9v	
	19f		10a	
	18c		11a	
	23f		12f	
			14	
			15b	

Wyeth	Pfizer	GSK	Who's Next	PPV
(Licensed)	(13-Valent)	(10-Valent)	(15 Valent)	(23 Valent
4	1	1	1	1 17f
6b	3	4	3	2 18c
9v	4	5	4	3 19a
14	5	6b	5	4 19f
19f	6a	7f	6a	5 20
18c	6b	9v	6b	6b 22f
23f	7f	14	7f	7f 23f
	9v	19f	9v	8 33f
	14	18c	14	9n
	19a	23f	18c	9v
	19f		19a	10a
	18c		19f	11a
	23f		22f	114 12f
			23f	121
			33f	15b

Pneumococcal Conjugate Vaccines

Pneumococcal Conjugate Vaccines

Wyeth (Licensed)	Pfizer (13-Valent)	GSK (10-Valent)	Who's Next (15 Valent)		Pfizer (20-Valent)		PV alent)
4	1	1	1	1	8	1	17f
6b	3	4	3	3	10A	2	18c
9v	4	5	4	4	11A	3	19a
14	5	6b	5	5	12F	4	19f
19f	6a	7f	6a	6a	15B	5	20
18c	6b	9v	6b	6b	22F	6b	22f
23f	7f	14	7 f	7f	33F	7f	23f
	9v	19f	9v	9v		8	33f
	14	18c	14	14		9n	001
	19a	23f	18c	19a		9v	
	19f		19a	19f		10a	
	18c		19f	18c		11a	
	23f		22f	23f		12f	
			23f	-01		14	
			33f			15b	





VZV & Shingles




ShingrixTM is a Great Vaccine

- Targets VZV glycoprotein E (gE) and ASO1_B adjuvant
- Adjuvant MPL + QS21 (oil-in-water + TLR4 agonist)
- Need 2 doses 2-6 months apart
- Works in very old and the immunocomprimised
- Recommended for >50 yo and can give to those who have had ZostavaxTM
- Recommended for those >50 yo who have had an episode of zoster








14

























Extrapolations are Dangerous but ...

If 15 million people are susceptible in the USA, and measles exposure is inevitable ... then the country can expect:

- 2,250,000-3,000,000 hospitalizations
- 37,000 deaths
- 20,000-30,000 cases of encephalitis
 50% with permanent neurologic deficits
- 600-1650 cases of SSPE

